Loading organizations...
§ Private Profile · 611 Gateway Blvd. Suite 120, South San Francisco, CA 94080
Medeor Therapeutics is a technology company.
Medeor Therapeutics develops cellular immunotherapies to improve outcomes for organ transplant recipients. The company employs chimeric approaches to induce long-lasting immune tolerance, aiming to reduce or eliminate the need for lifelong immunosuppression. Its clinical programs target immune and hematological diseases, initially focusing on kidney transplants.
Founded in 2014, Medeor Therapeutics began with the insight that a human immune system could be leveraged to benefit another. Dr. Steven Deitcher is associated with the company's inception, contributing to its foundational mission. This approach stems from a deep understanding of immune system modulation and transplant biology.
Medeor's therapies are designed for patients undergoing organ transplantation, especially kidney recipients, who currently endure chronic immunosuppression. The company's vision is to achieve a future where immune tolerance is routine, ultimately freeing these patients from the significant burdens and side effects of continuous immunosuppressant medication.
Medeor Therapeutics has raised $57.0M across 1 funding round.
Medeor Therapeutics has raised $57.0M in total across 1 funding round.
Medeor Therapeutics has raised $57.0M across 1 funding round. Most recently, it raised $57.0M Series B in November 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2017 | $57M Series B | Peter Kolchinsky | Flagship Ventures, 6 Dimensions Capital, Anand Mehra, Vivo Capital, WuXi Healthcare Ventures | Announced |
Medeor Therapeutics is a clinical-stage biotechnology company developing chimeric cellular immunotherapy, specifically MDR-101, to achieve immune tolerance in kidney transplant patients, reducing or eliminating the need for lifelong immunosuppressants.[1][2][4] It targets HLA-matched living donor kidney transplants, addressing organ rejection in patients with immune and hematological diseases, and has completed a Phase 3 registration trial with no reported organ loss due to acute rejection, though operations are now suspended while seeking acquirers to complete BLA filing.[1][2][4] The company serves transplant recipients and serves the unmet need for safer, long-term organ survival without chronic immunosuppression toxicities.[1][2]
Originating from over 20 years of Stanford research on mixed chimerism—where donor and recipient immune cells coexist harmoniously—Medeor has demonstrated promising results in clinical trials, including successful enrollment in its pivotal Phase 3 study funded partly by a $11.2M California Institute for Regenerative Medicine grant.[1][3][4]
Medeor Therapeutics was cofounded in 2012 as SERC Therapeutics by Stanford University School of Medicine professors Samuel Strober, Edgar Engleman, Robert Lowsky, and entrepreneur Chih Ping (CP) Liu, later renamed Medeor in 2014 to advance the Stanford-derived technology.[3] These founders collaborated for over 30 years on immune tolerance, pioneering mixed chimerism to reprogram immunity without graft-versus-host disease, building on Stanford milestones like Phase 2 trials published in the *American Journal of Transplantation* and early reports in *Transplantation*.[1][3]
The idea emerged from two decades of research starting at Stanford, evolving into a platform enabling clinical trials for tolerance in organ and hematopoietic cell transplants; key pivots included technology transfer to commercial GMP manufacturing and launching the Phase 3 program in HLA-matched living donor kidney transplants.[1][3][4]
Medeor rides the cell therapy and immune tolerance wave in biotech, targeting the chronic shortages and rejection risks in solid organ transplants amid rising end-stage kidney disease from aging populations and diabetes.[1][2][4] Timing aligns with advances in personalized immunotherapies post-CAR-T successes, where mixed chimerism offers a non-pharmacologic alternative to immunosuppressants, potentially disrupting a $3B+ market vulnerable to toxicities and non-adherence.[1][3]
Market forces favor it: regulatory momentum for tolerance-inducing therapies, CIRM funding, and peer-reviewed Phase 3 data under review amplify credibility, influencing the ecosystem by validating chimerism for broader applications like hematologic diseases and paving the way for acquirers to accelerate BLA approvals.[2][3][4]
Medeor's Phase 3 success positions it for acquisition-driven commercialization, with BLA filing as the immediate milestone to deliver MDR-101 to patients, potentially expanding to mismatched transplants and rare diseases.[2][4] Trends like AI-optimized cell manufacturing and combo therapies with gene editing will shape its path, evolving its influence from transplant pioneer to immune disease platform if partnered effectively—revitalizing the gift of transplantation as originally envisioned.[1][3][4]
Medeor Therapeutics has raised $57.0M in total across 1 funding round.
Medeor Therapeutics's investors include Peter Kolchinsky, Flagship Ventures, 6 Dimensions Capital, Anand Mehra, Vivo Capital, WuXi Healthcare Ventures.